Christopher M. Starr - 14 Jul 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Director
Issuer ticker: MNPR
Reported as of: 14 Jul 2025
Net transaction value: -$671,936
SEC form: 4
Accepted by SEC: 16 Jul 2025, 21:03:50 UTC
Prior SEC filing: 07 Mar 2025
Next SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Christopher M. Starr filed Form 4 for Monopar Therapeutics (MNPR) on 16 Jul 2025.

Key facts

This page summarizes Christopher M. Starr's Form 4 filing for Monopar Therapeutics (MNPR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jul 2025, 21:03.

Change

Previous filing in this sequence was filed on 07 Mar 2025.
Current net transaction value: -$671,936.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235470 Primary reporting owner

STARR CHRISTOPHER M

Relationship: Director
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 16 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $84
Shares: +16,800
Change %: +325%
Price: $0.005000
Shares after: 21,973
Date: 14 Jul 2025
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Sale

Transaction value: $672,020
Shares: -16,800
Change %: -76%
Price: $40.00
Shares after: 5,173
Date: 14 Jul 2025
Ownership: Direct
Footnotes: F2

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,880
Date: 14 Jul 2025
Ownership: See Footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Options

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -16,800
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 14 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,800
Exercise price: $0.005000
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This transaction involved a cash exercise of stock options.

Footnote F2

The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

9,880 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee

Footnote F4

Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.